Colgate-Palmolive (CL)
NYSE: CL
· Real-Time Price · USD
87.93
-1.21 (-1.36%)
At close: May 13, 2025, 3:59 PM
88.25
0.36%
Pre-market: May 14, 2025, 04:15 AM EDT
Colgate-Palmolive Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oral, Personal and Home Care Revenue | 15.62B | 15.17B | 14.25B | 14.11B | 13.59B | 13.17B | 13.16B | 13.16B | 12.93B | 13.82B | 15.02B | 15.21B | 14.93B | 14.56B |
| Oral, Personal and Home Care Revenue Growth | +2.97% | +6.41% | +1.02% | +3.84% | +3.19% | +0.09% | -0.05% | +1.79% | -6.45% | -7.99% | -1.23% | +1.90% | +2.49% | n/a |
| Pet Nutrition Revenue | 4.48B | 4.29B | 3.71B | 3.31B | 2.88B | 2.52B | 2.39B | 2.29B | 2.26B | 2.21B | 2.25B | 2.21B | 2.16B | 2.17B |
| Pet Nutrition Revenue Growth | +4.50% | +15.54% | +12.14% | +14.85% | +14.18% | +5.74% | +4.19% | +1.24% | +2.35% | -1.91% | +1.99% | +2.36% | -0.55% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 1.9B | 1.9B | 1.98B | 1.91B | 1.88B | 1.8B | 1.82B | 1.77B | 1.76B | 1.63B | 1.63B | 1.66B | 1.64B | 1.6B | 1.64B | 1.57B | 1.6B | 1.63B | 1.52B | 1.4B | 1.47B | 1.41B | 1.43B | 1.37B | 1.36B | 1.33B | 1.37B | 1.3B | 1.39B | 1.37B | 1.43B | 1.33B | 1.36B | 1.25B | 1.32B | 1.32B | 1.35B | 1.29B | 1.35B | 1.38B | 1.45B |
| Selling, General, and Administrative Revenue Growth | +0.11% | -4.19% | +3.56% | +1.65% | +4.27% | -1.04% | +3.05% | +0.57% | +7.65% | -0.06% | -1.39% | +0.98% | +2.69% | -2.32% | +4.34% | -2.31% | -1.71% | +7.58% | +8.82% | -5.30% | +4.32% | -1.19% | +4.38% | +0.29% | +2.79% | -2.99% | +5.31% | -6.61% | +1.38% | -3.92% | +7.20% | -2.13% | +8.70% | -5.22% | +0.15% | -2.51% | +5.29% | -4.53% | -2.46% | -4.76% | n/a |
| Research and Development Revenue | n/a | n/a | n/a | n/a | n/a | 343M | n/a | n/a | n/a | 320M | n/a | n/a | n/a | 307M | n/a | n/a | n/a | 290M | n/a | n/a | n/a | 281M | n/a | n/a | n/a | 277M | n/a | n/a | n/a | 285M | n/a | n/a | n/a | 289M | n/a | n/a | n/a | 274M | n/a | n/a | n/a |
| Research and Development Revenue Growth | n/a | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | n/a |